Gsk (GSK) Assets (2009 - 2026)

Gsk (GSK) has 10 years of Assets data on file, last reported at $81.3 billion in Q4 2025.

• In Q4 2025, Assets rose 6.52% year-over-year to $81.3 billion; the TTM figure through Dec 2025 stood at $301.4 billion (down 7.75% YoY), while the FY2025 annual figure was $81.3 billion, up 6.52% from the prior year.
• Assets advanced to $81.3 billion in Q4 2025, from $76.3 billion in the prior quarter.
• Across five years, Assets topped out at $106.6 billion in Q4 2021 and bottomed at $70.5 billion in Q4 2022.
• A 5-year average of $81.6 billion and a median of $76.3 billion in 2024 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets plunged 33.84% — and 2025, when it gained 6.52%.
• Year by year, Assets stood at $106.6 billion in 2021, then plunged by 33.84% to $70.5 billion in 2022, then climbed by 3.81% to $73.2 billion in 2023, then rose by 4.21% to $76.3 billion in 2024, then grew by 6.52% to $81.3 billion in 2025.
• The last three Assets figures came in at $81.3 billion (Q4 2025), $76.3 billion (Q4 2024), and $73.2 billion (Q4 2023), per Business Quant data.

Peer Comparison